HeyJaredThe Cancer Letter
The Cancer Letter, an independent weekly news publication, has been the leading source for information on the issues that shape oncology since 1973.With a dedicated audience of oncology’s leaders, The Cancer Letter stays on top of breaking news and advances in oncology,…
- Indexed episodes, last 90 days
- 13
- Latest publication
- Sep 16, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 8, 2026
Latest episodes
9/11, mRNA, musical chairs—and an assassination attempt (opens the original)
Read excerpt
This week’s oncology headlines run the gamut—from a discussion on the long-term consequences of 9/11 on lung cancer incidence, to the promise—and limits—of cutting edge mRNA science, to major institutional leadership changes, and even the intersection of cancer and war. In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher with The Cancer Letter, and Jacquelyn Cobb, managing editor, discuss the 25th anniversary of the 9/11 attacks in relation to toxic exposure and can
As daraxonrasib hits the clinic, Frank McCormick says RAS is bigger than pancreatic cancer (opens the original)
Read excerpt
Last month, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. In this week’s episode of In the Headlines, Jacquelyn Cobb, associate editor with The Cancer Letter , speaks with Frank McCormick, a leader in the KRAS space, about the history of RAS and where the field might b
Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field (opens the original)
Read excerpt
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The approval was much anticipated by patients and clinicians alike, ever since the dramatic results of the RASolute-302 trial, a randomized, open-label, multicenter clinical trial involving 500 adults with previ
Trump’s tariffs on generic drugs are “another wrinkle in an already unstable system” (opens the original)
Read excerpt
On July 21, President Donald Trump announced his latest set of sweeping tariffs on the pharmaceutical industry: a 200% levy on imported generic drugs by the year 2029. Trump imposed tariffs on branded drugs in April, which were met with concern about increased drug costs and decreased U.S. competitiveness in the global drug development market. However, a more dire concern—a familiar one—is arising now that tariffs are extended to generics: Shortages. At the time of the announcement, Jacquelyn Co
Raja Flores says oncology is loose with staging jargon, and now “it’s confusing my patients.” (opens the original)
Read excerpt
In last week’s issue of The Cancer Letter , Raja Flores wrote a guest editorial explaining how he, with his expertise in thoracic surgery, took issue with a nuance in a recent Keytruda commercial. In this week’s episode of In the Headlines, Flores spoke with Paul Goldberg, editor and publisher of The Cancer Letter , to explain how his deep dive into the issue led him to discover a broader issue in oncology: How loose terminology among oncologists, however innocuous or inconsequential it might se
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.